JP2019501139A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501139A5
JP2019501139A5 JP2018527232A JP2018527232A JP2019501139A5 JP 2019501139 A5 JP2019501139 A5 JP 2019501139A5 JP 2018527232 A JP2018527232 A JP 2018527232A JP 2018527232 A JP2018527232 A JP 2018527232A JP 2019501139 A5 JP2019501139 A5 JP 2019501139A5
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
variable region
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018527232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063624 external-priority patent/WO2017091745A1/en
Publication of JP2019501139A publication Critical patent/JP2019501139A/ja
Publication of JP2019501139A5 publication Critical patent/JP2019501139A5/ja
Priority to JP2021075689A priority Critical patent/JP7157204B2/ja
Pending legal-status Critical Current

Links

JP2018527232A 2015-11-25 2016-11-23 医薬製剤及びその使用 Pending JP2019501139A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021075689A JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562260104P 2015-11-25 2015-11-25
US62/260,104 2015-11-25
US201662368156P 2016-07-28 2016-07-28
US62/368,156 2016-07-28
PCT/US2016/063624 WO2017091745A1 (en) 2015-11-25 2016-11-23 Pharmaceutical formulations and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021075689A Division JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Publications (2)

Publication Number Publication Date
JP2019501139A JP2019501139A (ja) 2019-01-17
JP2019501139A5 true JP2019501139A5 (enExample) 2020-01-09

Family

ID=58763708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018527232A Pending JP2019501139A (ja) 2015-11-25 2016-11-23 医薬製剤及びその使用
JP2021075689A Active JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021075689A Active JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Country Status (9)

Country Link
US (3) US20170189548A1 (enExample)
EP (2) EP4335851A3 (enExample)
JP (2) JP2019501139A (enExample)
DK (1) DK3380525T3 (enExample)
ES (1) ES2970186T3 (enExample)
FI (1) FI3380525T3 (enExample)
PT (1) PT3380525T (enExample)
RS (1) RS65120B1 (enExample)
WO (1) WO2017091745A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
EP3778602B1 (en) * 2015-07-21 2023-07-12 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
CN111372610B (zh) * 2017-09-22 2023-05-30 伊缪诺金公司 防止免疫结合物中的甲硫氨酸氧化的方法
AU2019381628A1 (en) * 2018-11-12 2021-05-27 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
CN112996792B (zh) * 2018-11-12 2024-04-26 伊缪诺金公司 制备细胞毒性苯并二氮杂卓衍生物的方法
JP7585231B2 (ja) 2019-04-29 2024-11-18 イミュノジェン, インコーポレイテッド 抗cd123免疫複合体を含む治療的組み合わせ
JP2022544543A (ja) * 2019-08-15 2022-10-19 シルバーバック セラピューティックス インコーポレイテッド ベンザゼピンコンジュゲートの製剤およびその使用
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
WO2026034525A1 (ja) * 2024-08-07 2026-02-12 東レ株式会社 癌の治療および/または予防用医薬組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
BR9912053A (pt) 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
WO2002092127A1 (en) 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1534674A4 (en) 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
EA014640B1 (ru) 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EA020130B9 (ru) 2005-08-22 2014-10-30 Иммьюноджен, Инк. Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
AU2008269086B2 (en) * 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
ES2661466T3 (es) 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
GB2516808A (en) * 2013-05-31 2015-02-11 Innova Biosciences Ltd Antibody composition and buffer system therefor
FR3008463B1 (fr) 2013-07-10 2015-08-07 Hispano Suiza Sa Structure compacte de boitier d'entrainement pour turbomachine d'aeronef
SI3071237T1 (sl) * 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
DK2948184T3 (en) * 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv Duocarmycin-ADCs with improved in vivo antitumor activity
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
SI3313845T1 (sl) * 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina

Similar Documents

Publication Publication Date Title
JP2017536354A5 (enExample)
JP2018521638A5 (enExample)
JP2019535763A5 (enExample)
JP2015503909A5 (enExample)
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2020500538A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2010536384A5 (enExample)
JP2014511179A5 (enExample)
JP2016513682A5 (enExample)
JP2017533694A5 (enExample)
JP2017528476A5 (enExample)
JP2014512809A5 (enExample)
RU2016137110A (ru) Антитела к компоненту комплемента с5
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
RU2010123888A (ru) Axl-антитела
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP2011528902A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2018514193A5 (enExample)